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Abstract: The purpose of this study was to investigate the presence of Cryptococcus neoformans 
species complex isolates from environmental sources in Croatia and to determine their molecular 
types and antifungal susceptibility. Swab samples of tree hollows and bird excreta in the soil 
beneath trees were collected. Samples included 472 (92.73%) samples obtained from tree hollows 
and 37 (7.27%) samples from bird excreta. Four C. neoformans species complex isolates were 
recovered from tree hollow swabs along the Mediterranean coast, while there were no isolates 
recovered from bird excreta or from the continental area. Three isolates were identified as molecular 
types VNI and one as VNIV. All tested antifungals showed high in vitro activity against the four 
isolates. This is the first report proving the presence of C. neoformans species complex in the 
environment of Croatia. The results of the study suggest a major risk of exposure for inhabitants 
living along the Croatian coast and that both VNI and VNIV molecular types can be expected in 
clinical cases of cryptococcosis. Susceptibility to antifungals confirmed that no resistance should be 
expected in patients with cryptococcosis at the present time. 
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1. Introduction 
The encapsulated basidiomycetous yeasts of Cryptococcus neoformans and C. gattii species 
complexes are infectious agents of cryptococcosis, a life-threatening infection primarily affecting 
immunocompromised hosts [1]. While the C. neoformans species complex mainly affects patients with 
acquired immunodeficiency syndrome (AIDS) and those who are immunosuppressed (transplant 
patients, those on long-term corticosteroids, and those prescribed monoclonal antibodies), one-
quarter of patients with C. gattii species complex infections are immunocompetent and healthy. 
Infection of the brain and meninges by the C. neoformans species complex is the most important 
clinical manifestation in immunosuppressed individuals [2,3]. An estimated 220,000 cases of 
cryptococcal meningitis complicate HIV/AIDS worldwide each year, resulting in nearly 181,000 
deaths annually [3,4]. 
Infections by Cryptococcus species are acquired from environmental sources and are a 
consequence of the inhalation of dehydrated blastoconidia or basidiospores into the lungs. The yeasts 
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have been isolated from bird excreta, soil, bark and trunk hollows of trees, and decaying wood in 
various parts of the world [5].  
The use of antifungal agents, particularly in long-term suppressive regimens, has raised 
concerns about the development of drug resistance in C. neoformans species complex [6]. Globally, 
fluconazole-resistant strains of C. neoformans species complex have been increasingly reported in the 
past two decades. Geographical distribution shows that increasing fluconazole resistance is 
demonstrated in Africa, Asia, and Latin America, while low rates are still found in North America 
and Europe, except for Spain [6–8]. In Croatia, the clinical isolates investigated in one study showed 
no resistance either to fluconazole or other antifungals [9]. A few studies reporting the antifungal 
susceptibility of environmental C. neoformans species complex strains have been conducted, mainly 
in Brazil and India [10–12]. Such studies are significant because the susceptibility data of 
environmental isolates may influence the profiles of the clinical isolates recovered from patients 
because of the transmission pathway from environmental sources. However, such studies from 
Europe are lacking.  
The taxonomy of C. neoformans is still under major investigation [13–15,16]. The term “species 
complex” is used to comprise all genetic, pathogenic, epidemiological, ecological, and clinical 
differences between the strains [14]. C. neoformans species complex currently consists of five major 
molecular types distinguishable by several molecular techniques [17–21]: VNI, VNII, and VNB, with 
capsular antigen A (serotype A) and classified as C. neoformans var. grubii, VNIV with capsular 
antigen D (serotype D) and classified as C. neoformans var. neoformans, and VNIII, including diploid 
and aneuploid hybrids between the two varieties (AD hybrids). Molecular epidemiology data are 
important because they enable us to understand the population structure of the pathogen, its 
evolution, and how it is spreading across continents. In Europe, most cases of cryptococcosis are 
caused by isolates of the C. neoformans species complex, with VNI being the most prevalent molecular 
type, followed by VNIV and VNIII [5,22]. Genotyping of 48 clinical isolates obtained from 15 patients 
in Croatia was performed by amplified fragment length polymorphism (AFLP), showing a 
prevalence of 40% AFLP1/VNI, 40% AFLP2/VNIV, and 20% AFLP3/VNIII isolates [9]. At present, C. 
neoformans species complex strains from environmental sources in Croatia have not yet been isolated 
or investigated for antifungal susceptibility and molecular epidemiology.  
The purpose of this study was to investigate the presence of C. neoformans species complex 
isolates from environmental sources in Croatia and to determine their molecular types and antifungal 
susceptibility. The research results will provide the first insights into the ecology of Cryptococcus 
species in Croatia and thus the potential exposure risk of the inhabitants to these yeasts in the 
investigated urban locations. The antifungal susceptibility profile of C. neoformans isolated from 
environmental sources can indicate the susceptibility of clinical isolates and lead to the development 
of treatment guidelines. 
2. Materials and Methods 
2.1. Geographic and Climate Characteristics of Croatia 
The geography of Croatia is defined by its location in southeastern Europe along the 
Mediterranean coast (Figure 1). Due to this location at the meeting point of the Mediterranean, the 
Alps, and the Pannonian plain, Croatia exhibits great geographical and natural diversity. The largest 
part of Croatia has a moderately warm rainy climate under the Köppen classification, with a mean 
monthly temperature in the coldest month of the year above ‒3 °C and below 18 °C [23].  
2.2. Sample Collection, Cultures, and Identification 
Swab samples of tree hollows and bird excreta in the soil beneath trees were collected from 
different geographical areas in Croatia. Trees involved were identified to the species level whenever 
possible. The samples were collected from urban public places including squares, parks, gardens, 
hospital areas, and school playgrounds. Collecting and processing of swab samples was performed 
as described elsewhere [24]. Samples were cultured onto plates containing Niger seed agar incubated 
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at 27 °C and 37 °C for two weeks and were monitored daily. The dark brown colonies suggestive of 
cryptococcal colonies were subcultured on Sabouraud peptone dextrose agar plates (Liofilchem, 
Roseto degli Abruzzi, Italy). The number of brown colonies appearing on each culture plate was 
counted and recorded. Identification of C. neoformans by conventional mycological methods included 
the commercial identification system ID 32 C (BioMérieux, Marcy l’Etoile, France) based on the 
assimilation of carbohydrates and nitrate as well as the presence of capsule observed in India ink 
preparations. Up to 10 cryptococcal yeast colonies were stored in glycine buffer at −20 °C until 
antifungal susceptibility testing and molecular analysis were performed. 
2.3. Antifungal Susceptibility Testing 
Antifungal susceptibility of C. neoformans species complex isolates to flucytosine, amphotericin 
B, fluconazole, itraconazole and voriconazole were determined by ATB FUNGUS 3 (BioMérieux, 
Marcy l'Etoile, France). The test was performed according to the manufacturer’s instructions. Isolates 
were also tested with a standard broth microdilution method according to the Clinical Laboratory 
Standards Institute (CLSI) for amphotericin B, fluconazole, and voriconazole [25]. Since there are no 
clinical breakpoints defined by the CLSI for C. neoformans species complex, epidemiological cutoff 
values (ECV) were used as reference values to define a strain as wild type or non-wildtype [26,27]. 
Isolates were considered wild type when the minimal inhibitory concentration (MIC) value for 
amphotericin B was ≤0.5 μg/mL, for flucytosine ≤8 μg/mL, for fluconazole ≤8 μg/mL, for itraconazole 
≤0.25 μg/mL, for voriconazole ≤0.25 μg/mL. Susceptibility testing according to CLSI was done in 2019, 
two years after other investigations were already finished. For that reason, not all isolates (but two) 
were viable and available for testing. 
2.4. Molecular Analysis 
The molecular type and mating type of the isolates was determined by multiplex PCR, as 
previously described [18,28,29]. Strains H99 (VNI), WM626 (VNII), JEC21 (VNIV), and CBS 132 
(VNIII) were included as reference strains [19]. 
2.5. Statistical Analysis 
Statistical analysis included descriptive frequency tables, and Fisher’s exact test. Statistical 
significance was determined when p ≤ 0.05 was observed. 
3. Results 
3.1. Distribution of Samples According to Location, Sample Type, and Tree Species 
A total of 509 swab samples was collected, covering a wide territory of Croatia during summer 
and autumn 2013‒2016 (Figure 1). Fourteen Croatian towns were included in the study: Zagreb, 
Čakovec, Samobor, Varaždin, and Osijek in the continental area (n = 208, 40.86%), and Split, Rijeka, 
Rovinj, Šibenik, Korčula, Krk, Pula, Dubrovnik, and Makarska along the Mediterranean coast (n = 
301, 59.13%). Samples included 472 (92.73%) swab samples from tree hollows and 37 (7.27%) samples 
from bird excreta. A total of 46 different tree species were sampled (Table S1). Most of the trees were 
Olea europea (olive tree, 25.5%), Ceratonia siliqua (carob tree, 5.3%), Pinus sylvestris (scots pine, 5.1%), 
Betula pendula (silver birch, 4.5%), Castanea spp. (chestnut tree, 4.3%), and Prunus dulcis (almond tree, 
3.9%) [30].  
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Figure 1. (a) The map represents the geographic distribution of the environmental samplings. 
Locations marked in yellow indicate the towns where positive samples were recovered. The inset 
shows the geographic position of Croatia in Europe. (b) The number and type of sample collected in 
each of the 14 sampling locations. Dark blue bars, samples from tree hollows; light blue bars, samples 
of bird excreta in the soil beneath the trees. 
3.2. Cryptococcus spp. Isolates in Environmental Samples 
Four C. neoformans species complex isolates were identified during this study (4/509, 0.8%). All 
four isolates were recovered from cultures of tree hollow swabs collected in the Mediterranean area, 
while there were no isolates recovered from bird excreta or from samples collected in the continental 
area. The isolate from Rijeka was found in the hospital area and three isolates from the island of Krk 
were found along the promenade beside the sea. 
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Comparisons of positive samples between the two sample types, between samples collected in 
the Mediterranean and continental area, as well as between those recovered from olive trees and 
other tree species were not statistically significant. 
3.3. Molecular Characterization of C. neoformans Species Complex Isolates 
The four C. neoformans species complex isolates were classified into two different molecular 
types, VNI (n = 3) and VNIV (n = 1), all with mating type α (Figure 2). The three VNI isolates 
originated from two locations, Rijeka and Krk Island, whereas the VNIV isolate was found on Krk 
Island. Three isolates were found in tree hollows of O. europea, while one VNI isolate was also found 
in a tree hollow of a P. sylvestris. The only isolate found in P. sylvestris tree hollows originated from 
the town of Rijeka and the isolates recovered from O. europea were found on Krk Island. 
 
Figure 2. Multiplex PCR results showing mating type and molecular type identification of the four 
Croatian Cryptococcus neoformans species complex isolates. H99 and JEC21 represents the reference 
strains, VNI-αA and VNIV-αD, respectively. The 100 bp DNA ladder (Promega, Madison, WI, USA) 
was used as molecular DNA ladder. CROKRK = isolates from Krk Island; CROREJ = isolate from 
Rijeka. 
3.4. Antifungal Susceptibility of C. neoformans Species Complex Isolates 
Results obtained by the ATB FUNGUS 3 method showed that all isolates were as susceptible as 
wild-type strains, with MIC values very similar for all antifungals tested. Antifungal susceptibility 
according to the CLSI broth microdilution method, performed for one VNI and one VNIV isolate, 
confirmed the ATB FUNGUS 3 results (Table 1).  
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Table 1. Antifungal susceptibility of the four C. neoformans species complex isolates tested by ATB 
FUNGUS 3 and broth microdilution reported as minimal inhibitory concentration values (μg/mL). 
Location 
Molecular 
type 
5-FC  
(ECV = 8 
µg/mL) 
AMB 
(ECV = 0.5 
µg/mL) 
FLZ 
(ECV = 8 
µg/mL) 
ITZ 
(ECV = 0.25 
µg/mL) 
VOZ 
(ECV = 0.25 
µg/mL) 
ATB
F3 
CLSI  
ATBF
3 
CLSI  
ATBF
3 
CLSI ATBF3 CLSI ATBF3 CLSI  
Krk VNIV 4 - 0.5 0.25 1 4 0.125 - 0.06 0.25 
Krk VNI 4 - 0.5 - 1 - 0.125 - 0.06 - 
Krk VNI 4 - 0.5 - 1 - 0.125 - 0.06 - 
Rijeka VNI 4 - 0.5 0.25 2 4 0.125 - 0.06 0.125 
5-FC = 5-fluorocytosine; AMB = amphotericin B; FLZ = fluconazole; ITZ = itraconazole; VOZ = 
voriconazole; ECV = epidemiological cutoff value; ATBF3 = ATB FUNGUS 3 method; CLSI = CLSI 
standard broth microdilution method; - = not tested. 
4. Discussion 
This is the first report showing the presence of C. neoformans species complex isolates from 
environmental sources in Croatia along with their antifungal susceptibility and molecular 
characterization, which were only available for clinical isolates so far [9]. However, studies had 
previously been conducted in an attempt to find C. neoformans species complex in the environment 
in this geographical area. An extensive environmental survey was carried out during 2012–2015, 
representing 12 countries with 6436 samples, which documented the distribution of C. neoformans and 
C. gattii species complexes around the Mediterranean basin. Croatia was represented with 18 
environmental samples, but had no positive results [31]. Seasonal distribution cannot be the reason 
for not finding C. neoformans species complex in Croatia at the locations in the previous study because 
samples were collected each month by each of the collaborating groups. In that study, the peak of 
positive trees was observed during the spring. In our study, samples were also collected year-round, 
and all four isolates were found in May and June, which is in accordance with a previous study. 
However, the seasonal distribution cannot be analyzed because of the small number of positive 
samples. [31]. 
In our study, C. neoformans species complex isolates were found only in the environmental from 
the Mediterranean part of Croatia. Their recovery from tree hollows of O. europea and P. sylvestris is 
in agreement with the aforementioned study investigating C. neoformans species’ complex 
distribution around Mediterranean basin and demonstrating the presence of this species in samples 
from trees belonging mainly to the genera Eucalyptus, Olea, Ceratonia, and Pinus in Cyprus, France, 
Greece, Italy, Libya, Portugal, Spain, and Turkey [30]. Leaves and flowers were not sampled because 
in the study by Cogliati et al. no isolates were recovered from these sites [31]. 
Tree hollows, as an important environmental niche for C. neoformans species complex, have been 
investigated since the 1990s [32]. The affinity of Cryptococcus spp. with this environment had been 
explained in previous studies by its ability to produce laccase enzyme. Aside from the production of 
melanin, laccase is involved in the degradation of lignin, a polymer related to cellulose and an integral 
part of virtually all higher plants that provides rigidity to woody tissue [33]. In our study, VNI isolates 
were recovered from two tree species, O. europea and P. sylvestris, while the VNIV isolate was only 
recovered from O. europea. In a previous study involving the Mediterranean area, C. neoformans var. 
grubii colonized 12 different tree genera, confirming its ability to adapt to different environments and 
distribute globally. In contrast, C. neoformans var. neoformans showed a preference for trees typical of 
the subcontinental climate, such as Platanus, Prunus, and Quercus, probably reflecting its ability to 
tolerate lower temperature better than C. neoformans var. grubii. However, the climatic zones have 
unclear boundaries, enabling isolates belonging to different varieties to share the same tree species 
as a niche [31,34]. 
Although the authors intended to collect both types of samples (swab samples of tree hollows 
and bird excreta in the soil beneath trees) from every location where samples were collected, bird 
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excreta were difficult to find. The streets in towns were cleaned every day and samples were collected 
early in the morning; bird excreta were found only in two locations, Rovinj and Korčula. This may be 
a sign to other researchers investigating C. neoformans species complex in the environment that the 
improvement of sample collection techniques for this purpose is needed. The birds from which 
excreta were collected were not identified. 
Bird excreta, if collected at two locations, could be easily positive as well, assuming that both the 
birds and the decaying trees are an important part of the life cycle of the same organism, C. neoformans 
species complex. In the recent study by Springer et al., the authors demonstrated the broad 
importance of plants (and plant debris) as an ecological niche and reservoirs of infectious propagules 
of cryptococci in the environment. Cryptococci can undergo saprobic filamentation, mating, and the 
production of spores on dead plant material, indicating the potential for the long-term association of 
cryptococci with plant [35]. Therefore, it may be possible that birds are responsible for spreading, 
while plants may help with maintaining, optimizing, and enhancing virulence factors during the 
environmental lifecycle of this opportunistic pathogen. 
The distribution of molecular types VNI and VNIV in the environmental samples in Croatia was 
expected according to previous studies. VNI is the most prevalent molecular type in the 
Mediterranean basin, distributed from Portugal to Libya [5]. Molecular type VNIV, although less 
common than VNI, was already detected in the environment of Croatia’s neighboring countries, for 
example Italy [29,36]. In Greece, the VNIV is the most common molecular type, as well as in northern 
Turkey. Molecular types VNII, VNB, and VNIII were not detected in our study. So far, these types 
were detected in the Mediterranean basin from trees in Libya, Greece, and Turkey [29]. Although C. 
gattii species complex isolates were not found, their presence in Croatia, especially in the southern 
part of the country, cannot be excluded since this zone is characterized by a hot Mediterranean 
climate similar to that in the neighboring regions of southern Italy and Greece, where this pathogen 
has already been reported [29,36]. 
The molecular analysis of environmental isolates in Croatia demonstrated the presence of 
molecular types VNI and VNIV, which were already identified in clinical samples during previous 
studies. Molecular type VNIII has only been detected in clinical samples so far [5,9]. The impact of 
different molecular types on patient outcome in terms of clinical manifestations or attributable 
mortality rates is still unknown. Controversial results have been generated regarding the correlation 
between molecular types, virulence, and mortality rate [37,38].  
The tested antifungal compounds amphotericin B, 5-flucytosine, fluconazole, itraconazole, and 
voriconazole demonstrated high in vitro activity against environmental C. neoformans species 
complex isolates. This is in accordance with the antifungal susceptibility results for clinical isolates 
in a previous study in which all tested antifungals also showed high in vitro activity against C. 
neoformans isolates [9]. Some studies demonstrated differences in antifungal susceptibility among 
molecular types, but the correlation between the molecular type and antifungal susceptibility is still 
an open issue [39,40]. 
This is the first report proving the presence of C. neoformans species complex in the environment 
of Croatia. The results of the study show the potential risk of exposure for inhabitants, especially on 
the Croatian coast, to certain molecular types, particularly VNI and VNIV, which can be expected in 
clinical cases of cryptococcosis. Although a limitation of this study is the small number of detected 
environmental isolates, their antifungal susceptibility pattern suggests that no strains with low 
susceptibility to the most common antifungals should be expected in patients with cryptococcosis 
and no guideline modifications are needed at the moment. Further investigation regarding the 
correlation of molecular types with clinical outcome and antifungal susceptibility are warranted.  
Supplementary Materials: The following are available online at www.mdpi.com/2309-608X/5/4/99/s1. Table S1: 
Number of samples collected from different tree species in Croatia.  
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